SequelSEC

IDEXX LABORATORIES INC /DE IDXX

In Vitro & In Vivo Diagnostic Substances · CIK 0000874716 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$4.55B
Fiscal year ended 2026-06-30
Operating income
$1.46B
Fiscal year ended 2026-06-30
Free cash flow
$1.25B
Fiscal year ended 2026-06-30

IDEXX LABORATORIES INC /DE (IDXX) reported revenue of $4.55B and net income of $1.14B for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from IDEXX LABORATORIES INC /DE’s SEC filings, each linked to the filing it came from. It is classified by the SEC under In Vitro & In Vivo Diagnostic Substances.

Income

IDEXX LABORATORIES INC /DE income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$4.55B
Cost of revenue$1.71B
Gross profit$2.84B
Operating income$1.46B
Net income$1.14B
Research & development$261.46M
Weighted-average diluted sharesUnavailable
Pretax income$1.42B
Income tax expense$284.76M
Diluted EPSUnavailable
Selling, general & administrative$1.12B
General & administrative$450.48M
Selling & marketing$672.74M

Balance

IDEXX LABORATORIES INC /DE balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$196.93M
Total assets$3.44B
Current assets$1.51B
Total liabilities$1.83B
Current liabilities$1.29B
Total equity incl. NCI$1.61B
Temporary (mezzanine) equityUnavailable
Inventory$391.58M
Accounts receivable$627.08M
Goodwill$410.95M
Long-term debt$299.86M
Accounts payable$129.10M

Cash flow

IDEXX LABORATORIES INC /DE cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$1.37B
Capital expenditures$117.18M
Investing cash flow-$132.04M
Financing cash flow-$1.21B
Net change in cash$32.34M
Stock-based compensation$62.97M
Common dividends paidUnavailable
Common share repurchases$1.18B
Depreciation & amortization$154.08M

Derived

IDEXX LABORATORIES INC /DE derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$1.25B
Gross margin62.4%
Operating margin32.0%
FCF margin27.5%
SBC / revenue1.4%
Current ratio1.17x
Revenue YoY growth12.8%
Net margin25.0%
R&D / revenue5.7%
CapEx / revenue2.6%
Long-term debt / equity0.19x
Effective tax rate20.0%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IDXX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-20View SEC filing
10-Q · Filed 2025-11-03View SEC filing
10-Q · Filed 2025-08-04View SEC filing
10-Q · Filed 2025-05-01View SEC filing

Companies in the same industry

ACHV AWHL BMRA BZYR CDIO CLDX ICCC IMDX LNTH MYGN NEOG NTLA

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.